On Monday, Shares of Pulte Group, Inc. (NYSE:PHM), lost -0.66% to $18.10.
Pulte Group, declared that it will release its fourth quarter 2015 financial results before the market opens on Thursday, January 28, 2016. The Company will hold a conference call to discuss fourth quarter results that same day at 8:30 a.m. (ET).
Pulte Group, Inc., through its auxiliaries, engages in the homebuilding business; mortgage banking operations; and title operations in the United States. The company is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on land.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), inclined 0.28% to $69.17, during its last trading session.
Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb (BMY), declared that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), counting diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). This is the second of two trials being conducted under a formerly declared clinical trial partnership agreement between Bristol-Myers Squibb Company and Seattle Genetics. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a marker expressed on Hodgkin lymphoma (HL) and several types of NHL, which combines the targeting ability of a monoclonal antibody with a highly potent cell-killing agent. Recent preclinical data suggest that ADCETRIS causes immunogenic cell death of tumor cells, providing rationale for combination with Opdivo, a human antibody that targets and inhibits the programmed death receptor-1 (PD-1), resulting in T-cell activation. Opdivo is part of a new class of cancer immunotherapy treatments known as checkpoint inhibitors, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system.
“This is the second corporate-sponsored clinical trial to evaluate ADCETRIS combined with a checkpoint inhibitor to determine if the combination can improve patient outcomes,” said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. “This study is a part of a broad development program that comprises more than 70 ongoing clinical trials evaluating ADCETRIS in multiple lines of therapy for Hodgkin and non-Hodgkin lymphoma and as part of novel combinations that could result in improved clinical benefit with manageable safety profiles. Our aim is to establish ADCETRIS as the foundation of care for CD30-expressing lymphomas.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, SUPERVALU INC. (NYSE:SVU), ended its last trade with 1.57% gain, and closed at $7.12.
Moments ago, Trader’s Choice released new research updates concerning several important developing situations counting the following equities: AU Optronics Corp (AUO), Ocera Therapeutics Inc. (OCRX), Solar3D Inc. (SLTD) and SUPERVALU Inc. (SVU). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Highlights from recently’s reports comprise:
On Monday, December 21, 2015, Nasdaq Composite ended at 4,968.92, up 0.93%, Dow Jones Industrial Average advanced 0.72%, to finish the day at 17,251.62, and the S&P 500 closed at 2,021.15, up 0.78%.
- AU Optronics Corp’s stock advanced 15.18% to close Monday’s session at USD 2.96. The share price vacillated between USD 2.85 and USD 3.10. The stock recorded a trading volume of 5.85 million shares, which was above its 50-day daily average volume of 1.81 million shares and above its 52-week average volume of 1.87 million shares. Over the last three days AU Optronics Corp’s shares have advanced 11.28% while in the past one week the shares have moved up 22.31%. In the past one month, the stock registered a gain of 10.04%. Meanwhile, in the last six months the stock has lost 37.95% and year to date the shares have shed 38.83%. Further, the company is trading at a price to earnings ratio of 4.70. This compares to a historical PE ratio of 9.54. The stock is at a Price to Sales (ttm) ratio of 0.22 and Price to Book (mrq) ratio of 0.44.
- SUPERVALU Inc.’s stock reduced 0.77% to close Monday’s session at USD 6.48. The company’s shares fluctuated in the range of USD 6.37 and USD 6.58. A total of 6.53 million shares exchanged hands, which surpassed its 50-day daily average volume of 3.73 million shares and was above its 52-week average volume of 3.82 million shares. Over the last three days, SUPERVALU Inc.’s shares have declined by 5.40% while in the past one week it has moved up 0.47%. Furthermore, over the last three months, the stock has lost 17.77% and in the past six months, the shares have shed 24.12%. Further, the company is trading at a price to earnings ratio of 12.46. This compares to a historical PE ratio of 21.74. Additionally, the stock is trading at a price to cash flow ratio of 3.19 and price to sales ratio of 0.10.
SUPERVALU INC., together with its auxiliaries, operates as a grocery wholesaler and retailer in the United States. The company operates through three segments: Independent Business, Save-A-Lot, and Retail Food. The Independent Business segment offers wholesale distribution of various food and non-food products to independent retail customers, such as single and multiple grocery store independent operators, regional chains, and the military.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
